Clinical Trial Update: Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating chemoradiation followed by durvalumab for poor-risk and/or elderly patients with stage III non-small-cell lung cancer was terminated,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Rush University Medical Center | Conditions: Stage III Non-small-cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-05-28